Inhibikase stock rises ~10% as FDA lifts clinical hold on Parkinson’s study

Inhibikase stock rises ~10% as FDA lifts clinical hold on Parkinson’s study
Inhibikase Therapeutics ( NASDAQ: IKT) stock rose ~12% on Wednesday after the company said that the U.S. Food and Drug Administration (FDA) lifted a clinical hold on IkT-148009 in Parkinson's disease ... read more
Source: Bing NewsPublished on 2023-01-25